1. Damaira Pharmaceuticals stake acquisition - On 31 March 2026 Astonea acquired 25.74% of Damaira Pharmaceuticals for ₹6.25 Cr, funded by reallocating unutilised IPO proceeds. Damaira reported turnover of ₹82.48 Cr in its latest audited financials, roughly 55% of Astonea's own FY25 revenue, adding a substantial equity-accounted earnings stream from a business that reported nil turnover two years prior.
2. US subsidiary operationalisation - Astonea LLC was incorporated in Wyoming on 25 January 2026 as a wholly-owned subsidiary and management has made its operationalisation a strategic priority for FY 2026-27, targeting incremental revenue from US market penetration. A dedicated US commercial entity removes the intermediary step in the company's largest regulated export market, allowing direct customer relationships and full-margin sales.
3. Haripur land acquisition for manufacturing expansion - A \~1-acre land parcel at Haripur, Panchkula was acquired on 13 February 2026 for ₹2 Cr to expand manufacturing and plant operations. The site sits adjacent to the existing Haripur facility and, once developed, directly increases the company's production footprint to support the export and CDMO pipelines management is targeting.
4. IPO balance-sheet reset - The June 2025 IPO raised ₹37.66 Cr in fresh equity, lifting shareholders' funds from ₹18.41 Cr to ₹57.13 Cr, cutting short-term borrowings from ₹31.67 Cr to ₹21.47 Cr, and reducing the debt-to-equity ratio from 1.32x to 0.36x. A halved interest burden and a clean balance sheet free up internal cash generation for the capex and R&D priorities outlined across FY 2026-27.
5. Export market registration programme - Management guidance for FY 2026-27 explicitly calls out incremental revenue from new export geographies, including a Bolivia registration programme for export-grade ointments, alongside continued penetration in Guatemala, Peru, Iraq, and Yemen. Each completed registration opens a new non-regulated market where the company can place existing formulations with minimal additional R&D spend.
6. Own-brand portfolio deepening - Management has made deepening the 'Glow Up' (cosmetics) and 'Regero' (pharma) own-brand portfolio a strategic priority for FY 2026-27, targeting Tier-II and Tier-III Indian cities through B2B distribution and B2C e-commerce. Own-brand sales carry structurally higher margins than third-party contract manufacturing, so a mix shift toward branded revenue would expand the OPM from the 9-15% range seen in recent periods.
7. CDMO capability leverage for global partnerships - The company has scaled contract manufacturing across tablets, softgels, and creams and is actively positioning its CDMO services to capture global pharma and cosmetic partnerships. A single medium-sized CDMO contract from a regulated-market customer would add a multi-year, high-retention revenue stream that absorbs the fixed cost of the upgraded Raipur Rani facility.